Compare

Longeveron Inc. vs China SXT Pharmaceuticals, Inc. vs IGC Pharma, Inc. vs Cannapharmarx, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearLongeveron Inc.
LGVN
China SXT Pharmaceuticals, Inc.
SXTC
IGC Pharma, Inc.
IGCLast annual report: year ended 2025-03-31
Cannapharmarx, Inc.
CPMD
Year ended2025-12-312026-03-312025-03-312025-12-31
Revenue$1.20M$1.14M$1.27M$1.36M
Revenue growth (YoY)-49.9%-34.6%-5.5%+66.1%
Gross margin67.0%21.9%48.7%-153.1%
Operating marginn/m-625.9%-585.8%-245.8%
Net marginn/m-545.2%-560.3%-817.2%
Net income-$22.70M-$6.21M-$7.12M-$11.13M
EPS (Diluted)-$1.29-$9.13-$0.09-$0.02
Operating cash flow-$18.64M-$4.02M-$4.79M-$789.1K
Free cash flow-$18.89Mn/a-$4.91M-$794.6K
Cash & equivalents$4.66M$28.18M$405.0K$1.8K
Total assets$10.26M$34.75M$8.75M$7.02M
Total liabilities$4.59M$5.05M$2.42M$37.17M
Shareholders' equity$5.67M$29.71M$6.33M-$30.15M
Return on year-end equity-400.1%-20.9%-112.5%n/a
Shares outstandingn/an/a80.88M662.50M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearLongeveron Inc.China SXT Pharmaceuticals, Inc.IGC Pharma, Inc.Cannapharmarx, Inc.
Latest$1.20M
Ended 2025-12-31
$1.14M
Ended 2026-03-31
$1.27M
Ended 2025-03-31
$1.36M
Ended 2025-12-31
1 year earlier$2.39M
Ended 2024-12-31
$1.74M
Ended 2025-03-31
$1.34M
Ended 2024-03-31
$820.1K
Ended 2024-12-31
2 years earlier$709.0K
Ended 2023-12-31
$1.93M
Ended 2024-03-31
$911.0K
Ended 2023-03-31
$0
Ended 2023-12-31
3 years earlier$1.22M
Ended 2022-12-31
$1.97M
Ended 2023-03-31
$397.0K
Ended 2022-03-31
$0
Ended 2022-12-31
4 years earlier$1.31M
Ended 2021-12-31
$2.60M
Ended 2022-03-31
$898.0K
Ended 2021-03-31
$0
Ended 2021-12-31